O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*Toshio Shimizu,Aaron Lisberg,Jacob Sands,Jonathan Greenberg,Penny Phillips,Naoyuki Tajima,Y. Kawasaki,Jessie Gu,Fumiaki Kobayashi,Noboru Yamamoto,Melissa Lynne Johnson,Funda Meric-Bernstam,Kiyotaka Yoh,Edward B. Garon,Rebecca S. Heist,Alexander I. SpiraAnnals of Oncology（2021）引用 24|浏览6暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
